ANNEE 2012

Publié le 21/02/2013 à 10h04 (mis à jour le 24/07/2023 à 10h23)


Saulière A, Bellot M, Paris H, Denis C, Finana F, Hansen JT, Altié MF, Seguelas MH, Pathak A, Hansen JL, Sénard JM, Galès C. Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nature Chemical Biology 2012, 8, 622-630.

Genet G, Guilbeau-Frugier C, Honton B, Dague E, Schneider MD, Coatrieux C, Calise D, Cardin C, Niéto C, Payré B, Dubroca C, Marck P, Heymes C, Dubrac A, Arvanitis D, Despas F, Altié MF, Séguélas MH, Delisle MB, Davy A, Sénard JM, Pathak A, Galès C. Ephrin-B1 is a novel specific component of the lateral membrane of the cardiac tissue architecture cohesion. Circ Res 2012, 110, 688-700.

Denis C, Saulière A, Galandrin S, Sénard JM, Falès C. Probing heterotrimeric G Protein activation : application to biased ligands. Curr Pharm Des 2012, 18, 128-44.

Maïga A, Mourier G, Quinton L, Rouget C, Gales C, Denis C, Lluel P, Sénard JM, Palea S, Servent D, Gilles N. G protein-coupled receptors, an unexploited animal toxin targets : exploration of green mamba venom for novel drug candidates active against adrenoceptors. Toxicon 2012, 15, 487-96.

Engeli S, Birkenfeld AL, Badin M, Bourlier V, Louche K, Viguerie N, Thalamas C, Montastier E, Larrouy D, Harant I, de Glisezinski I, Lieske S, Reinke J, Beckmann B, Langin D, Jordan J, Moro C. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest 2012, 122, 4675-9.


Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, Vuillaume I, Corvol JC, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha- Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Sablonniere B, Azulay JP, Tison F, Rascol O, Vidailhet M, Destée A, Bloem BR, Bordet R, Devos D ; for the Parkgait-II study group. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson’s disease undergoing subthalamic stimulation : a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012,11, 589-596.

Rascol O, Ferreira J, Nègre-Pages L, Perez-Lloret S, Lacomblez L, Galitzky M, Lemarié JC, Corvol JC, Brotchie JM, Bossi L. A Proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson’s disease. Fund Clin Pharmacol 2012, 26, 557-564.

Lees A, Fahn S, Eggert KM, Jankovic J, Lang A, Micheli F, Maral Mouradian M, Oertel WH, Olanow CW, Poewe W, Rascol O, Tolosa E, Squillacote D, Kumar D. Perampanel an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson’s Disease. Mov Disorders 2012, 27, 2, 284-300.

Rascol O, Barone P, Behari M, Emre M, Giladi N, Olanow W, Ruzicka E, Bibbiani F, Squillacote D, Patten A, Tolosa E. Perampanel in Parkinson disease fluctuations : a double-blind randomized trial with placebo and entacapone. Clin Neuropharmacol 2012, 35, 15-20.

Mizuno Y, Yamamoto M, Kuno S, Hasegawa K, Hattori N, Kagimura T, Sarashina A, Rascol O, Schapira AH, Barone P, Hauser RA, Poewe W. Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa-Undertreated Parkinson Disease : A Double-Blind, Randomized Trial.Clin Neuropharmacol. 2012, 35, 174-181.

Rascol O, Bronzova J, Hauser RA , Lang AE , Sampaio C , Theeuwes A , Van de Witte SV , for the Mondrian Study Group. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations : Results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism & Related Disorders 2012, 18, 370-376.

Krismer F, Seppi K, Tison F, Sampaio C, Zangerl A, Peralta C, Yekhlef F, Ghorayeb I, Ory-Magne F, Galitzky M, Bozi M, Scaravilli T, Colosimo C, Geser F, Rascol O, Poewe W, Quinn NP, Wenning GK. The unified multiple system atrophy rating scale : intrarater reliability. Mov Disord 2012, 27, 13, 1683-85.

Damon-Perrière N, Foubert-Samier A, Cochen De Cock V, Gerdelat-Mas A, Debs R, Pavy-Le Traon A, Senard JM, Rascol O, Tison Fand Meissner WG. Assessment of the Scopa-Aut questionnaire in Multiple System Atrophy : Relation to UMSARS scores and progression over time. Parkinsonism Rel Disord 2012, 18, 612-615.

Dellapina E, Ory-Magne F, Regragui W, Thalamas C, Lazorthes Y, Rascol O, Payoux Brefel-Courbon C. Effect of suthalamic deep brain stimulation on pain in Parkinson’s disease. Pain 2012, 153, 2267-73.

Sagaspe P, Taillard J, Amiéva H, Beck A, Rascol O, Dartigues JF, Capelli A, Philip P. Influence of age, circadian and homeostatic processes on inhibitory motor control : a go/nogo task study. PLoS One. 2012, 7:e39410.

Ratti PL, Terzaghi M, Minafra B, Repetto A, Pasotti C, Zangaglia R, Pacchetti C, Manni R. REM and NREM sleep enactment behaviors in Pakinson’s disease, Parkinson’s disease dementia and dementia with lewy bodies. Sleep Medicine 2012, 13, 926-32.

Millar Vernetti P, Perez-Lloret S, Rossi M, Cerquetti D, Merello M. Validation of a new scale to access olfactory dysfunction in patients with Parkinson’s disease. Parkinsonism and related disorders 2012, 18, 4, 358-61.

Perez-Lloret S, Mezas Rojas G, Menoni MC, Ruiz G, Velazquez C, Rodriguez H, Rey MV, Cardinali D. Pregabalin beneficial effects on sleep quality of life are poorly correlated with reduction on pain intensity after an 8-week treatment course. Clin Neuropharmacol 2012, 35, 1, 21-4.

Perez-Lloret S, Nègre-Pagès L, Ojero-Senard A, Damier P, Destée A, Tison F, Merello M, Rascol O ; COPARK Study Group. Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson’s disease : preliminary analysis from the French COPARK cohort. Eur J Neurol 2012, 19, 28-37

Perez-Lloret S, Rascol O. Parkinson disease : Serotonin reuptake inhibitors for depression in PD. Nat Rev Neurol 2012, 8, 365-366.

Perez-Lloret S, Rey MV, Dellapina E, Pellaprat J, Brefel-Courbon C, Rascol O. Emerging analgesic drugs for Parkinson’s disease. Expert Opin Emerg Drugs 2012, 17, 157-171.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, Montastruc JL, Rascol O. Prevalence and Pharmacological factors associated with impulse-control disorders symptoms in patients with Parkinson disease. Clin Neuropharmacol 2012, 35, 261-5.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Senard JM, Pavy-Le Traon A, Montastruc JL, Rascol O. Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord. 2012, 18, 501-5.

Lesage S, Condroyer C, Klebe S, HonoréA, Brefel-Courbon C, Durr A, Brice A. Identification of VPS 35 mutations replicated in French families with Parkinson disease. Neurology 2013, 78, 1449-50.

Montastruc F, Schwarz N, Schmitt L, Bui E. An overview of the symptoms and typical disorders associated with Alice in wonderland syndrome. Neuropsychiatry 2012, 2, 281-9.

Chaveron D, Silva S, Sanchez-Verlaan P, Conil JM, Sommet A, Geeraerts T, Génestal M, Minville V, Fourcade O. The 90 % effective dose of a sufentanil bolus for the management of painful positioning in intubated patients in the ICU. Eur J Anaesthesiol 2012, 29, 280-285.

Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Vaillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL. Réajkumar V, Spencer A, Chevret S, Nobili-Escruva C, Petillon MO, Olivier P, Cristini C, Llau ME. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. NEJM 2012, 366, 1782-91.

Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, D.Struthers A, Adriaan V, Ruilope ML, Bakris LG, O’Connor C, Gheorgiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, SFilippatos G, Massy AZ, Pathak A, Pina IL, SabbahH, Sica AD, Tavazi L, Pitt B. Minéralocorticoïde receptor antagonist for heart failure with reduced ejection fraction : integrating evidence into clinical practice. Eur Heart J 2012, aout, 2782-95.

Goudev A, Berrou JP, Pathak A. Effect of eprosartan-based therapy on systolic blood pressure and total cardiovascular risk in a large international population : preliminary report of the observational POWER study. Vasc Health Risk Manag 2012, 8, 563-8.

Despas F, Lambert E, Vaccaro A, Labrunée M, Franchitto N, Lebrin M, Galinier M, Sénard JM, Lambert G, Murray E, Pathak A. Peripheral chemoreflex activation contributes to sympathetic baroreflex impairment in chronic heart failure. J Clin Hypertens 2012, 30, 753-60.

Petrella RJ, Shlyakhto E, Konradi AO, Berrou JP, Sedefdjian A, Pathak A, OSCAR Publication group. Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension : a retrospective subgroup analysis of the observational study on cognitive function and SBP reduction (OSCAR) study. J Clin Hypertens 2012, 14, 78-84.

Arnaudis B, Lairez O, Escamilla R, Fouilloux A, Fournier P, Monteil B, Bouisset F, Arnal JF, Elbaz M, Carrié D, Roncalli J, Pathak A, Galinier M. Impact of chronic obstructive pulmonary disease severity on symptoms and prognosis in patients with systolic heart failure. Clin Res Cardiol 2012, 101, 717-26.

Guiraud T, Granger R, Gremeaux V, Bousquet M, Richard L, Soukarie L, Babin T, Labrnuée M, Bosquet L, Pathak A. Accelerometer as a tool to assess sedentarity and adherence to physical activity recommendations after cardiac rehabilitation program. Annals of Physical and Reha Med 2012, 55, 293-374.

Guiraud T, Granger R, Gremeaux V, Bousquet M, Richard L, Soukarié L, Babin T, Labrunée M, Sanguignol F, Bosquet L, Golay A, Pathak A. Telephone support oriented by accelerometric measurements enhances adherence to physical activity recommendations in noncompliant patients after a cardiac rehabilitation program. Arch of Physical Med and Rehab 2012, 93, 2141-7.

Solerno JU, Perez Chada D, Guinjoan SM, Perez Lloret S, Hedderwick A, Vidal MF, Cardinali DP, Vigo DE. Cardiac autonomic activity predicts dominance in verbal over spatial reasoning tasks : results from a preliminary study. Autonomic Neuroscience : Basic and Clinical 2012, 167, 78-80.

Pathak A, Girerd X, Azizi M, Benamer H, Halimi JM, Lantelm P. Renal denervation for the treatment of arterial hypertension. Journal de Radiologie Diagnostique et interventionnelle 2012, 42, 414-22.

Sénard JM, Despas F, Pathak A. Dysautonies centrales. Hupotension orthostatique. Presse Méd 2012, 41, 1122-7.

Labrunée M, Gremeaux V, Guiraud T, Sanguignol F, Golay A, Pathak A. Education thérapeutique du patient dans les pathologies cardiovasculaires. Arch Cardiovasc Dis Suppl 2012, 4, 299-309.

Labrunée M, Pathak A, Loscos M, Coudeyre E, Casillas JM, Gremeaux V. Therapeutic education in cardiovascular diseases : state of the art and perspectives. Ann Phys Rehab Med 2012, 55, 322-341.

Sénard JM, Pathak A, Pavy-Le Traon A. Troubles dysautonomiques. Le livre de l’Interne, Neurologie, 2012, 128-140.

Sénard JM. Hypotension orthostatique : physiopathologie, diagnostic et traitements. EMC Cardiologie 2012, 7, 1-18.

Meissner WG, Foubert-Samier A, Dupouy S, Gerdelat-Mas A, Debs R, Marquant F, Cochen de Cock V, Rascol O, Tison F, Pavy-le Traon A. Assessment of quality of life with the multiple system atrophy health-related quality of life scale. Mov Disorders 2012, 12, 1574-7.


Moulis G, Béné J, Sommet A, Sailler L, Lapeyre-Mestre M, Montastruc JL and The French Association of PharmacoVigilance Centres. Statin-induced lupus : a case/non-case study in a nationwide pharmacovigilance database. Lupus 2012, 21, 885-9.

Moulis G, Sailler L, Montastruc JL. Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins. A case-control study. Pharmacoepidemiol Drug Saf 2012, 21, 900-1.

Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Montastruc JL and the French Association of Regional Pharmacovigilance Centers. Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins : a case-control study. Pharmacoepidemiol Drug Saf 2012, 21, 314-319.

Moulis G, Sommet A, Durrieu G, Bagheri H, Lapeyre-Mestre M, Montastruc JL and The French Association of Pharmacovigilance centres. Trends of reporting of "serious" vs. "non serious" adverse drug reactions over time : a study in the French PharmacoVigilance database. Br J Clin Pharmacol 2012, 74, 201-204.

Moulis G, Sommet A, Sailler L, Lapeyre-Mestre M, Montastruc JL, The French Association Of Regional Pharmacovigilance Centers. Drug-induced immune thrombocytopenia : A descriptive survey in the French PharmacoVigilance database. Platelets 2012, 23,490-4.

Moulis G, Sommet A, Béné J, Montastruc F, Sailler L, Montastruc JL, Lapeyre-Mestre M. Cancer risk of anti-TNF- α at recommended doses in adult rheumatoid arthritis : a meta-analysis with intention to treat and per protocol analyses. PLOS 2012, 7(11) : e48991.

Fournier JP, Lapeyre-Mestre M, Sommet A, Dupouy J, Poutrain JC, Montastruc JL. Laboratory monitoring of patients treated with antihypertensive therapy and newly exposed to non steroidal anti-inflammatory drugs. PLoS One 2012, 7, 3, e34187.

Fournier JP, Sommet A, Bourrel R, Oustric S, Pathak A, Lapeyre-Mestre M, Montastruc JL. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification : a population-based cohort study. Eur J Clin Pharmacol 2012, 68, 1533-40.

Danton AC, Montastruc F, Sommet A, Durrieu G, Bagheri H, Bondon-Guitton E, Lapeyre-Mestre M, Montastruc JL. Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions : a pharmacovigilance study in France. Eur J Clin Pharmacol 2012, Sep 21.

Montastruc F, Sommet A, Bondon-Guitton E, Durrieu G, Bui E, Bagheri H, Lapeyre-Mestre M, Schmitt L, Montastruc JL. The importance of drug-drug interactions as a cause of adverse drug reactions : a pharmacovigilance study of serotoninergic reuptake inhibitors in France. Eur J Clin Pharmacol 2012, 68, 767-775.

Gardette V, Lapeyre-Mestre M, Coley N, Cantet C, Montastruc JL, Vellas B, Andrieu S. Antipsychotic use and mortality risk in community-dwelling Alzheimer’s disease patients : evidence for a role of dementia severity. Curr Alzheimer Res 2012, 9, 1106-1116.

Sommet A, Durrieu G, Lapeyre-Mestre M, Montastruc JL and The Association of French PharmacoVigilance Centres. A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006. Pharmacoepidemiol Drug Saf 2012, 21, 285-288.

Maschino F, Hurault-Delarue C, Chebbane L, Fabry V, Montastruc JL, Bagheri H ; French Association of Regional Pharmacovigilance Centers. Bleeding adverse drug reactions (ADRs) in patients exposed to antiplatelet plus serotonin reuptake inhibitor drugs : analysis of the French Spontaneous Reporting Database for a controversial ADR. Eur J Clin Pharmacol 2012, 68, 1557-60.

Bondon-Guitton E, Bagheri H, Montastruc JL and The French Network of Regional PharmacoVigilance Centers. Drug-induced gingival overgrowth : a study in the French Pharmacovigilance Database. J Clin Periodontol 2012, 39, 513-518.

Hillaire-Buys D, Faillie JL, Montastruc JL, Petit P. Stay vigilant : a glitazone (pioglitazone) can hide a glitazar !. Eur J Clin Pharmacol 2012, 68, 1681-83.

Caillet C, Moachon L, Montastruc JL, Bagheri H, French Association of Regional Pharmacovigilance Centers. Safety profile of enantiomers versus racemic mixture : it’s the same ? Br J Clin Pharmacol 2012, 74, 886-89.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Montastruc JL, Rascol O. Do Parkinson’s disease patients disclose their adverse events spontaneously ? Eur J Clin Pharmacol 2012, 5, 857-65.

Perez-Lloret S, Rey MV, Bondon-Guitton E, Rascol O, Montastruc JL. Drugs associated with restless legs syndrome : a case/non case study in the French Pharmacovigilance database. J Clin Psychopharmacol 2012, 32, 827-7.

Paludetto MN, Olivier-Abbal P, Montastruc JL. Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France ? Pharmacoepidemiol Drug Saf 2012, 21, 1289-94.

Durrieu G, Palmaro A, Pourcel L, Caillet C, Faucher A, Jacquet A, Ouaret S, Perault-Pochat MC, Kreft-Jais C, Castot A, Lapeyre-Mestre M, Montastruc JL. First french experience of ADR reporting by patients after a mass immunization campaign with influenza A (H1N1) pandemic vaccines. Drug Saf 2012, 35, 845-854.

Braillon A, Bewley S, Herxheimer A, Mansfield P, Lexchin J, Menkes DB, Ziganshina LE, Montastruc JL. Marketing versus evidence-based medicine. Lancet 2012, 380, 340.

Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, Ge D, Shianna KV, Daly AK, Lucena MI, Nelson MR, Molokhia M, Aithal GP, Floratos A, Pe’er I, Serrano J, Bonkovsky H, Davern TJ, Lee WM, Navarro VJ, Talwalkar JA, Goldstein DB, Watkins PB, drug-induced injury network , DILIGEN, EUDRAGENE (Bondon-Guitton E, Spanish DILI registry. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 2012, 22, 784-95.

Jacquot J, Gony M, Baudrin D, Chastel X, Montastruc JL, Bagheri H. Could we Improve Notification of Adverse Drugs Reactions in Hospital ? Assessment of 5 Years of Network PharmacoMIP’s Activities. Therapie 2012, 67, 231-6.

Moulis G, Batz A, Durrieu G, Viard C, Decramer S, Montastruc JL. Severe neonatal hypercalcemia related to maternal exposure to nutritional supplement containing Spirulina. Eur J Clin Pharmacol 2012, 68, 221-222.

Ferrie B, Dupouy J, Lassoued S, Oustric S, Durrieu G, Rouge-Bugat ME, Montastruc JL. Myopathie sévère par intoxication à la colchicine : à propos d’un cas. Thérapie 2012, 67, 482-3.

Lefort A, Arlet P, Bagheri H, Campistron E. Hypomagnésémie avec hypocalcémie sous oméprazole. Thérapie 2012, 67, 191-2.

Blazejewski S, Girodet PO, Orriols L, Capelli A, Moore N, CESIR Group. Factors associated with serious traffic crashes : a prospective study in southwest France. Arch Intern Med 2012, 172, 1039-41.

Orriols L, Queinec R, Philip P, Gadegbeku B, Delorme B, Moore N, Suissa S, Lagarde E ; CESIR Research Group. Risk of injurious road traffic crash after prescription of antidepressants. J Clin Psychiatry 2012, 73, 1088-94.

Avalos M, Adroher ND, Lagarde E, Thiessard F, Grandvalet Y, Contrand B, Oriols L ; CESIR Research Group. Prescription-Drug-Related risk in driving : comparing conventional and lasso shrinkage logistic regressions. Epidemiology 2012, 23, 706-12.

Roulet L, Asseray N, Foucher N, Potel G, Lapeyre-Mestre M, Ballereau F. Etude des comportements d’automédication chez les patients admis dans un service d’urgences médicales. Thérapie 2012, 67, 447-55.

Montastruc F, Montastruc G, Vigreux P, Bruneval P, Guilbeau-Frugier C, Cron C, Bagheri H, Delisle B, Lapeyre-Mestre M, Pathak A, Montastruc JL. Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, ’Ecstasy’). Br J Clin Pharmacol 2012, 74, 547-548.

Jouanjus E, Pourcel L, Saivin S, Molinier L, Lapeyre-Mestre M. Use of multiple sources and capture-recapure method to estimate the frequency of hospitalization related to drug abuse. Pharmacoepidemiol Drug Saf 2012, 21, 733-41.

Sommet A, Ferrières N, Jaoul V, Cadieux L, Soulat JM, Lapeyre-Mestre M, Montastruc JL. Use of drugs, tobacco, alcohol and illicit substances in a french student population. Thérapie 2012, 67, 429-35.

Gass-Jégu F, Damase-Michel C, Hurault-Delarue C, Bourrel R, Montastruc JL. Analysis of Prescriptions associated to Hormone Replacement Therapy in Midi-Pyrénées Region. Therapie 2012, 67, 121-8.

Lacroix I, Hurault-Delarue C, Montastruc JL, Damase-Michel C. Can benfluorex induce congenital malformations ? Diabetes Metab 2012, 38, 373-4.

Franchitto N, Cabot C, Dumonteil N, Bounes V, Pathak A, Rouge D. A prehospital acute coronary syndrome in a cocaine user : an unstable clinical situation. J Med Toxicol 2012, 8, 80-2.

Bordenave H, Despas F, Sommet A, Montastruc JL. Patient’s Medicine Cabinet Composition Study of 207 Families in France. Therapie 2012, 67, 137-43

Stamenkovic S, Solesse A, Zanetti L, Zagury P, Vray M, et le groupe "Intérêt de santé publique et études post-inscription (ISPEP) Lapeyre-Mestre M. Guide de la Haute Autorité de Santé (HAS) : les études post inscription sur les technologies de santé (médicaments, dispositifs médicaux et actes) : principes et méthodes. Thérapie 2012, 67, 409-211.

Cornu C, Camberlein C, Binquet C, Robert C, Vigouroux C, Bouyssou C, Felin A, Dupont-Mordelet MF, Sailly A, Kubiak C, Poli G, Gueguen S, Duchesne C, Ploix S, Thalamas C. Manuel de bonnes pratiques professionnelles des centres d’investigation clinique. Thérapie 2012, 67, 11-42.

Bounhoure JP, Montastruc JL. Risque hémorragique et syndromes coronariens aigus chez les sujets âgés. Bull Acad Natle Méd 2011, 195, 1981-1987.

Castel M, Despas F, Modesto A, Gales C, Honton B, Galinier M, Sénard JM, Pathak A. Effets indésirables cardiaques des chimiothérapies. Press Med 2012, 41, 1122-27.

Mias C, Genet G, Pathak A, Sénard JM, Galès C. Le réveil des cardiomyocytes adultes résidents. Médecine Sciences 2012, 28, 1103-9.

Herxheimer A, Vohra S, Montastruc JL, Edwards R. A major rethink is needed on reporting adverse drug reactions. Br Med J 2012, 345, e6379.

Terzaghi M, Ratti PL, Manni F, Manni R. Sleep paralysis in narcolepsy : more than just a motor dissociative phenomenom ? Neurol Sci 2012, 33, 169-72.

Abadie D, Roussin A. Le tramadol, un analgésique à effet opioîde, noradrenergique et sérotoninergiques : gare aux effets indésirables, interactions médicamenteuses et à la pharmacodépendance. Bulletin Audois d’Information de Pharmacologie 2012, Juin.

Bouscaren N. Le dopage génétique : des souris (transgéniques) et des hommes. Bulletin d’Information de l’AMPD 2012, 7-8.

PDF Damase-Michel C, Lacroix I. - Prescrire mieux et plus sûr. Trait d’Union 2012, 135, 6. [4.4 Mo]

Lapeyre-Mestre M. Benzodiazépines et apparentés. Une consommation scrutée de très près par l’Afssaps. Porphyre 2012, Mars.

Lapeyre-Mestre M. Les benzo de A à Z. L’Infirmière Libérale Magazine 2012, Mars.

Lapeyre-Mestre M. Dépendance à l’alcool. Le baclofène devient un outil acceptable pour l’ANSM. Porphyre 2012. Juin.

Lapeyre-Mestre M. Buprénorphine : faut-il sevrer ? La revue du Praticien 2012, Février.

Montastruc JL. Prescrire avec parcimonie, attention et indépendance. Question Santé 2012. Février.

Montastruc JL. Pharmacovigilance en 2011. La Lettre d’Information des programmes qualité et de la certification 2012 du CHU de Toulouse. Juin.

Montastruc JL, Bien utiliser le paracétamol sans abîmer son foie. Que Choisir Santé 2012, 60, 13.

Montastruc JL Quels vrais nouveaux médicaments en Médecine libérale ? Bulletin Audois d’Information de Pharmacologie 2012, Mai.

Montastruc JL, Lapeyre Mestre M. Pharmacovigilance et PharmacoEpidémiologie. Liris 2012, 9, 5.

Montastruc JL, Montastruc F. Abadie D, Bagheri H. Développer la pharmacovigilance. Pratiques 2012, 59, 81-83.

Montastruc JL, Montastruc F. Which role for regional PharmacoVigilance centers (RPVC) in the new european pharmacovigilance regulation ? Gac Med Bilbao 2012, 109, 2-3.

Montastruc JL. Détournement d’usage du topiramate. La Revue Prescrire 2012, 32, 394.

Montastruc JL. Diurétiques dans l’HTA : encore et toujours en 2012 ! Ou les 100 jours de la chlorthalidone. Bulletin Audois d’Information de Pharmacologie 2012, Juin.

Montastruc JL. Les accidents domestiques ne sont pas une fatalité. Participation au dossier paru dans la revue de la SSMP 2012, 152, 12-13.

Montastruc JL. Nicotine et dopage. Sports et Santé 2012, 23, 7.

Montastruc JL. Quel vrai intérêt du suivi intensif de la glycémie dans le diabète de type 2 ? Bulletin Audois d’Information de Pharmacologie 2012, Juin.

Montastruc JL. La prescription des médicaments chez la personne âgée. Projet de communiqué. Académie Nationale de Médecine

Pathak A. Comment intégrer les produits de triple et double combinaison et de monothérapie dans un concept total pour le soin d’hypertension ? Journal de Cardiologie 2012, Février.

Pathak A. Les génériques : l’avis du pharmacologue. Diabète et Obésité 2012, 63.

Pathak A. Lien entre l’hypertension artérielle et la fonction cognitive. Journal de la Cardiologie 2012.